Literature DB >> 18318434

Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta.

Masashi Kitazawa1, Dan N Trinh, Frank M LaFerla.   

Abstract

OBJECTIVE: Inclusion body myositis (IBM) is an inflammatory muscle disease, although the role of inflammation remains to be elucidated. Here, we address the mechanisms by which inflammation modulates Abeta and tau, two hallmark features of this disease.
METHODS: A transgenic mouse model of IBM was utilized in which acute and chronic inflammation was induced via lipopolysaccharide. The effects of inflammation were assessed by analyzing the myopathological and the behavioral phenotype. Human IBM skeletal muscle biopsies were investigated to determine concordance with data from the animal model.
RESULTS: Both acute and chronic lipopolysaccharide exposure augmented infiltration by CD8(+) cytotoxic T cells and increased amyloid precursor protein steady-state levels in skeletal muscle, whereas increased Abeta generation was observed only in chronically treated mice. Both acute and chronic inflammation enhanced tau phosphorylation in skeletal muscle. The mechanism underlying this effect was mediated by the tau kinase, glycogen synthase kinase-3beta (GSK-3beta). Suppression of GSK-3beta activity using either a specific inhibitor or lithium chloride significantly reduced tau phosphorylation and partially rescued motor impairment. In human IBM muscle, GSK-3beta and phospho-tau were colocalized, further supporting the pathogenic role of GSK-3beta in this disease. Using C2C12 myoblast cultures, we found that GSK-3beta was activated by proinflammatory cytokines (interleukin-1beta, interleukin-6, tumor necrosis factor-alpha), leading to enhanced tau phosphorylation.
INTERPRETATION: Our results identify a molecular mechanism by which proinflammatory stimuli affect tau pathology via the GSK-3beta signaling pathway in skeletal muscle.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18318434     DOI: 10.1002/ana.21325

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

Review 1.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

2.  Restoration of lipoxin A4 signaling reduces Alzheimer's disease-like pathology in the 3xTg-AD mouse model.

Authors:  Haley C Dunn; Rahasson R Ager; David Baglietto-Vargas; David Cheng; Masashi Kitazawa; David H Cribbs; Rodrigo Medeiros
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

Review 3.  [Standard treatment for myositis and muscular dystrophies].

Authors:  J Schmidt; M Vorgerd
Journal:  Nervenarzt       Date:  2011-06       Impact factor: 1.214

4.  Inflammation induced by infection potentiates tau pathological features in transgenic mice.

Authors:  Michael Sy; Masashi Kitazawa; Rodrigo Medeiros; Lucia Whitman; David Cheng; Thomas E Lane; Frank M Laferla
Journal:  Am J Pathol       Date:  2011-04-30       Impact factor: 4.307

5.  Lipopolysaccharide-induced tau phosphorylation and kinase activity--modulation, but not mediation, by corticotropin-releasing factor receptors.

Authors:  Allyson D Roe; Michael A Staup; Jordi Serrats; Paul E Sawchenko; Robert A Rissman
Journal:  Eur J Neurosci       Date:  2011-07-04       Impact factor: 3.386

6.  Aberrant cell cycle reentry in human and experimental inclusion body myositis and polymyositis.

Authors:  Bumsup Kwon; Pravir Kumar; Han-Kyu Lee; Ling Zeng; Kenneth Walsh; Qinghao Fu; Amey Barakat; Henry W Querfurth
Journal:  Hum Mol Genet       Date:  2014-02-20       Impact factor: 6.150

Review 7.  Nonimmune mechanisms of muscle damage in myositis: role of the endoplasmic reticulum stress response and autophagy in the disease pathogenesis.

Authors:  Andrea Henriques-Pons; Kanneboyina Nagaraju
Journal:  Curr Opin Rheumatol       Date:  2009-11       Impact factor: 5.006

Review 8.  Inclusion body myositis: review of recent literature.

Authors:  Steven A Greenberg
Journal:  Curr Neurol Neurosci Rep       Date:  2009-01       Impact factor: 5.081

9.  Immunization with amyloid-beta attenuates inclusion body myositis-like myopathology and motor impairment in a transgenic mouse model.

Authors:  Masashi Kitazawa; Vitaly Vasilevko; David H Cribbs; Frank M LaFerla
Journal:  J Neurosci       Date:  2009-05-13       Impact factor: 6.167

Review 10.  Inclusion-body myositis: muscle-fiber molecular pathology and possible pathogenic significance of its similarity to Alzheimer's and Parkinson's disease brains.

Authors:  Valerie Askanas; W King Engel
Journal:  Acta Neuropathol       Date:  2008-10-31       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.